Lung cancer is the leading cause of cancer-related deaths worldwide.2 In the U.S, the average five-year survival rate for all stages of non-small cell lung cancer (the most common kind) is only 30%,3 with detrimental impact: lung cancer accounts for more deaths than colorectal, breast, and prostate cancers combined.4 One reason for the low survivability is that about 64% of patients are diagnosed at a nonlocalized stage,5 meaning the lung cancer is detected after it has spread beyond the initial tumor. For these patients, time is critical.
Get in touch for additional information about Ion and to have your questions answered.
Thank you for your submission.
Ion endoluminal system
As with any bronchoscopic procedure under general anesthesia, serious complications may include bleeding, pneumothorax (collapsed lung), cardiac-related complications, respiratory failure, air embolism, or death. For summary of the risks associated with bronchoscopy refer to www.intuitive.com/safety.
For risks, cautions, and warnings and full prescribing information, refer to the associated Ion System user manual(s) or visit https://manuals.intuitivesurgical.com/market.
Individuals’ outcomes may depend on a number of factors, including but not limited to patient characteristics, disease characteristics, and/or physician/surgeon experience.